Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Free Access

A Population-Based Study of the Association between Trypanosoma cruzi Infection and Cognitive Impairment in Old Age (The Bambuí Study)

Lima-Costa M.F.a, b · Castro-Costa E.a–c · Uchôa E.a, b · Firmo J.a, b · Ribeiro A.L.P.b · Ferri C.P.c · Prince M.c

Author affiliations

aPublic Health and Ageing Research Group, Oswaldo Cruz Foundation René Rachou Institute, and bFederal University of Minas Gerais Medical School, Belo Horizonte, Brazil; cHealth Service and Population Research Department, Institute of Psychiatry, King’s College London, London, UK

Corresponding Author

M.F. Lima-Costa

Laboratório de Epidemiologia e Antropologia Médica, Centro de Pesquisas René Rachou da Fundação Oswaldo Cruz, Av. Augusto de Lima, 1715

CEP: 30190-002, Belo Horizonte, MG (Brazil)

Tel. +55 31 3349 7730, Fax +55 31 3295 3115, E-Mail lima-costa@cpqrr.fiocruz.br

Related Articles for ""

Neuroepidemiology 2009;32:122–128

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Background: Limited clinical data suggest that chronic Trypanosoma cruzi infection, which causes Chagas’ disease (ChD), is associated with cognitive impairment. This study investigated this association in a large population-based sample of older adults. Methods: Participants in this cross-sectional study comprised 1,449 persons aged ≥60 years from a Brazilian endemic area (Bambuí). Cognitive functioning was ascertained by the Mini-Mental State Examination (MMSE), considering its score in percentiles [≤14 (<5th percentile), 15–22 (5th to <25th) and ≥23]. Hypothesized risk factors were T. cruzi infection, ChD-related electrocardiographic (ECG) abnormalities and use of digoxin medication. Potential confounders included depressive symptoms, smoking, stroke, hemoglobin, HDL cholesterol, blood glucose, systolic blood pressure, and use of psychoactive medication. Results: The prevalence of T. cruzi infection was 37.6%. There was a graded and independent association between infection and the MMSE score (adjusted odds ratios estimated by ordinal logistic regression = 1.99; 95% CI 1.43–2.76). No significant associations between the MMSE score and ECG abnormalities or digoxin medication use were found. Conclusions: This study provides for the first time epidemiological evidence of an association between T. cruzi infection and cognitive impairment which was not mediated by either ChD-related ECG abnormalities or digoxin medication use.

© 2008 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: July 03, 2008
Accepted: September 12, 2008
Published online: December 16, 2008
Issue release date: February 2009

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 2

ISSN: 0251-5350 (Print)
eISSN: 1423-0208 (Online)

For additional information: http://www.karger.com/NED


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.